Therapeutic cloning bill: first steps to overthrow ban
07 November, 2006 by Kate McDonaldThe Australian Senate has today taken the first steps in overturning the ban on therapeutic cloning, voting 35 to 31 in favour of a private member's bill recommending the adoption of the Lockhart Review.
Latest buzz: marijuana may slow progression of Alzheimer's disease
23 October, 2006 by ABN StaffNew evidence in rats suggests that marijuana may contain compounds that slow the memory loss associated with Alzheimer's disease.
Needle-free psoriasis treatment progresses
20 October, 2006 by ABN StaffPeople suffering from severe psoriasis may soon find symptom relief without injections, after a cream-based treatment being developed by Sydney biotechnology company Apollo Life Sciences outperformed current market-leading drugs in pre-clinical studies.
Odd spot: testosterone bad for brains
05 October, 2006 by ABN StaffA Yale University School of Medicine study shows for the first time that a high level of testosterone, such as that caused by the use of steroids to increase muscle mass or for replacement therapy, can lead to a catastrophic loss of brain cells.
Breathtaking results in Alzheimer's drug trial
21 September, 2006 by Graeme O'NeillWhen the news of remarkable results in a pre-clinical trial of a potential drug for Alzheimer's disease was released in July, the headlines screamed and the share price for Prana Biotechnology went through the roof. Graeme O'Neill probes the details.
Heart smart: new drug improves blood flow
12 September, 2006 by External Press Release AuthorA new drug has been shown to improve blood flow in diseased arteries, reducing the risk of high blood pressure and heart attacks, a Monash University study has revealed.
Melanoma vaccine trial raises eyebrows
21 July, 2006 by Kate McDonaldA trial of a vaccine for stages II and III melanoma didn't turn out as expected, so the researchers tried it in stage IV patients, causing a few surprises.
Seek and destroy mission for molecular assassin
20 July, 2006 by External Press Release AuthorAn experimental drug designed to seek out and destroy a gene associated with vascular disease is providing effective in early animal trials.
Vaccine researcher critical of CSL, govt approaches to bird flu
02 March, 2006 by Helen SchullerA leading researcher has raised the ire of CSL (ASX:CSL), saying the Melbourne company is "making the wrong vaccine for bird flu."
Monash team in new prostate cancer find
24 February, 2006 by Ruth BeranA team at Monash Institute of Medical Research in Melbourne has grown a human prostate from embryonic stem cells, and hopes the discovery will lead to better understanding of what causes prostate cancer.
CSL posts record profit and upgrade
22 February, 2006 by Ruth BeranMelbourne's CSL (ASX:CSL) today reported a net profit after tax of AUD$176.4 million for the first half of the financial year, up 34 per cent from the previous first half, and has upgraded its full year profit forecast by about 15 per cent to $335 to $350 million.
HealthLinx and Cryptome embark on a future together
21 February, 2006 by Ruth BeranThe first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.
Zenyth, MuriGen collaborate on inflammation targets
20 February, 2006 by Ruth BeranZenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases.
Oncomere discoveries open new avenues in cancer research
20 February, 2006 by Graeme O'NeillThe junk DNA revolution has thrown up yet another neologism for cancer geneticists to add to their spellcheckers: 'oncomere'.
QIMR scientists to trial malaria vaccine
16 February, 2006 by Ruth BeranScientists at the Queensland Institute of Medical Research (QIMR) are planning to commence a phase I clinical trial in Brisbane for a new malaria vaccine starting late this year or early next year.
